Vous êtes ici

BPCO et activité du petit matin

D. Piperno,*, M. Decavèle


[1] GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. 2013 [update 2013]; Available from www.goldcopd.org/ uploads/users/fi les/GOLD_Report_2013_Feb20

[2] Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med 2012;27:426-35.

[3] Espinosa de los Monteros MJ, Peña C, Soto Hurtado EJ, Jareño J, Miravitlles M. Variability of respiratory symptoms in severe COPD. Arch Broncopneumol 2012;48:3-7.

[4] Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8.

[5] Kuyucu T, Güçlü SZ, Saylan B, Demir C, Senol T, Güner S; Turkey SUNRISE Study Group. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks 2011;59:328-39.

[6] Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72.

[7] Calverley PM, Lee A, Towse L, Van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airfl ow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-60.

[8] Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airfl ow obstruction and resting hyperinfl ation in patients with COPD. Chest 2006;129:509-17.

[9] Postma DS, Koëter GH, vd Mark TW, Reig RP, Sluiter HJ. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airfl ow obstruction. Chest 1985;87:653-7.

[10] Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990;45:190-4.

[11] Casale R, Pasqualetti P. Cosinor analysis of circadian peak expiratory fl ow variability in normal subjects, passive smokers, heavy smokers, patients with chronic obstructive pulmonary disease and patients with interstitial lung disease. Respiration 1997;64:251-6.

[12] Dawkins KD, Muers MF. Diurnal variation in airfl ow obstruction in chronic bronchitis. Thorax 1981;36:618-21. [13] Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airfl ow limitation. Am Rev Respir Dis 1992;146:935-40.

[14] Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to bio- markers. Eur Respir J 2008;31:416-69.

[15] Small M, Broomfi eld S, Pollard R, Fermer S. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities. Poster ERS sept 2012. Available online: www.ersnetsecure.org/public/ prg_congres.abstract?ww_i_presentation=59408

[16] Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Basta M, et al. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep 2010;33:1159-64.

[17] Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD: a review. Respir Med 2011;105:1422-33.

[18] Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.

[19] Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3:1-11.

[20] Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/ formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50.

[21] Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010;36:96-104.

[22] United States Food and Drug Administration: Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009;74:65132-3.

[23] Palsgrove A, Houghton K, Hareendran A, Schaefer M, Setyawan J, Mocarski M, et al. The development of the early morning symptoms of COPD instrument (EMSCI). Poster presented at the International Society for Pharmacoeconomic and Outcomes Research Annual European Congress. Madrid, Spain, November 5-8, 2011. 2003;58:855-60.

Auteurs correspondants

*Auteurs correspondants.
Adresses e- mail : dpiperno@centremedicalparot.fr (D. Piperno).


D. Piperno1,*, M. Decavèle2

1Centre médical Parot, 54 rue Duquesne 69006 Lyon, France
2DES pneumologie Ile-de-France, DESC réanimation médicale ; Service de pneumologie et réanimation, Groupe hospitalier Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital, 75013 Paris, France

Liens d'intérêts

  • D. Piperno : AstraZeneca, Almirall, Boehringer-Ingelheim, Chiesi, GSK.
  • M. Decavèle a déclaré n’avoir aucun lien d’intérêts pour cet article.